Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€4.15 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.69B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationA marquee collaboration with Janssen provides durable development and commercialization leverage: it can supply upfront/research funding, milestone paths and potential royalty streams, de-risking portions of R&D and improving long-term commercialization probability versus solo development.
Proprietary PlatformA platform technology that augments radiotherapy and may stimulate immune responses supports multi-indication expansion and repeated use across tumor types. Platform assets create structural product optionality, licensing leverage, and long-term competitive differentiation if clinical benefits persist.
Top-line ImprovementA pronounced 2025 revenue rebound with very high gross margin indicates commercial or partner-led revenue traction and favorable economics at the unit level. If sustained, this demonstrates the business can scale revenue with attractive direct margins, aiding long-term viability.
Bears Say
Chronic Cash BurnPersistent negative operating and free cash flow erodes runway and forces recurring external financing. Over months this increases dilution risk, diverts management time to capital raises, and constrains the firm’s ability to fund multiple trials or commercial rollouts without partner funding.
Weak Balance SheetNegative shareholders' equity combined with rising debt materially weakens financial flexibility and increases refinancing risk. This structural capital weakness reduces negotiating leverage with partners or lenders and raises vulnerability to adverse funding conditions over the medium term.
Revenue VolatilityHighly inconsistent revenue history undermines predictability for R&D planning and commercialization. Volatility complicates budgeting, may reflect milestone-dependent receipts rather than recurring sales, and makes it harder to demonstrate stable commercial demand to partners or payors.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €4.15 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.69B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 73 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―